1. HBW Insight
  2. >>Beauty
  3. >>Business
  4. >>Earnings

J&J Producing Tylenol ‘24-7’ As US OTC Sales Jump 35% On Pandemic-Driven Stockpiling

 
• By Eileen Francis

J&J is prioritizing Tylenol production on caplets easiest to manufacture to maximize output as it manufactures the line around the clock, says CEO Alex Gorsky. First-quarter US OTC sales soared 35% as consumers stockpiled due to COVID-19, though the pandemic led J&J to downgrade its 2020 outlook.

Tylenol Boxes

Johnson & Johnson is making Tylenol analgesics around the clock, prioritizing formulations easiest to produce to maximize output, after unprecedented consumer stockpiling in response to COVID-19 drove a 35.9% surge in its OTC drug sales in the US during the first quarter.

The first major consumer health company to report quarterly results since spread of a novel coronavirus reached pandemic level, J&J said domestic OTC sales reached $689m during the January-March period as COVID-19

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

IFF Offsets Tariffs’ Impact, But Discretionary Product Ingredients Face Risk

 
• By Eileen Francis

New York-based International Flavors & Fragrance, Inc. has shifted procurement to alternative supply sources and is balancing production across its global network in response to US tariffs, though company executives say ingredients for discretionary products face risk.

Coty Lowers FY25 Forecast On Tariff Uncertainty, Inventory Reductions, But Expects Sunnier Days In FY26

 
• By Eileen Francis

Coty lowers its revenue and profit outlook for FY25, though it believes FY26 will be a better year thanks to a return of ‘blockbuster’ product launches, market expansion and mitigation strategies for current economic uncertainties.

Estee Lauder Lowers FY 2025 Outlook, Expects Positive Results FY 2026 On ‘Beauty Reimagined’

 
• By Eileen Francis

The Estee Lauder Companies reported a 10% drop in reported sales during its fiscal third quarter presentation on a 28% decline in travel retail organic sales. The firm, which lowered its FY 2025 sales expectations, says it expects positive growth in FY 2026.

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually

 
• By Eileen Francis

The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.

More from Business

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually

 
• By Eileen Francis

The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.

NAD Refers Men’s Hair Color Brand To FTC For Non-Compliance With Fast-Track SWIFT Decision

 
• By Eileen Francis

Plano, Texas-based Simpler Hair Color Inc. may face FTC enforcement action after it failed to comply with the National Advertising Division’s recommendations it discontinue the claim, “Rated #1 Men’s Hair Color,” associated with a consumer review website.

Beiersdorf Repositioning In China Will Get Boost From Thiamidol Launch

 
• By Eileen Francis

Beiersdorf AG hit some initial bumps with a repositioning of its business in China, but the firm is optimistic about the rollout of Thiamidol Skin Care In 2026.